A Study to Evaluate the Efficacy and Safety of Herceptin® (Trastuzumab) in Combination With Arimidex® (Anastrozole) an Aromatase Inhibitor Compared to Arimidex® Alone in Patients With Metastatic Breast Cancer
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00022672 |
|
Recruitment Status :
Completed
First Posted : January 27, 2003
Results First Posted : June 13, 2013
Last Update Posted : June 13, 2013
|
Sponsor:
Hoffmann-La Roche
Collaborator:
Genentech, Inc.
Information provided by (Responsible Party):
Hoffmann-La Roche
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Brief Summary:
This 2 arm study assessed the safety and efficacy of adding intravenous trastuzumab (Herceptin®) to daily oral anastrozole (Arimidex®) tablets as first- and second-line treatment in postmenopausal patients with human epidermal growth factor receptor-2 (HER2) overexpressing metastatic breast cancer (ER+ve and/or PR+ve). Patients were randomized to receive either anastrazole 1 mg per os (po) daily, or anastrazole 1 mg po daily + a loading dose of Herceptin® 4 mg/kg intravenous (iv) followed by weekly doses of Herceptin® 2 mg/kg iv. The anticipated time on study treatment was until disease progression, and the target sample size was 100-500 individuals.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Breast Cancer | Drug: trastuzumab (Herceptin®) Drug: anastrazole (Arimidex®) | Phase 3 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 208 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Randomized, Open-label Study of the Effect of Herceptin Plus Arimidex Compared With Arimidex Alone on Progression-free Survival in Patients With HER2-positive and Hormone-receptor Positive Metastatic Breast Cancer |
| Study Start Date : | January 2001 |
| Actual Primary Completion Date : | October 2009 |
| Actual Study Completion Date : | October 2009 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Breast cancer
MedlinePlus related topics:
Breast Cancer
| Arm | Intervention/treatment |
|---|---|
|
Experimental: trastuzumab + anastrozole
Trastuzumab 4 mg/kg loading dose intravenous (iv) over 90 minutes, followed by weekly doses of 2 mg/kg iv over 30 minutes plus 1 mg oral dose of anastrozole every day for 24 Months in the Main phase and in the Extension Phase.
|
Drug: trastuzumab (Herceptin®)
4mg/kg iv loading dose, followed by 2mg/kg iv weekly
Other Name: Herceptin® Drug: anastrazole (Arimidex®) 1 mg tablet taken orally daily
Other Name: Arimidex® |
|
Active Comparator: anastrozole
1 mg oral dose of anastrozole every day for 24 Months in the Main phase. In the Extension Phase participants could cross-over to also receive trastuzumab 4 mg/kg initial loading dose intravenous (iv) over 90 minutes, followed by weekly doses of 2 mg/kg iv over 30 minutes.
|
Drug: anastrazole (Arimidex®)
1 mg tablet taken orally daily
Other Name: Arimidex® |
Primary Outcome Measures :
- Progression Free Survival (PFS) [ Time Frame: 24 Months, End of Study (Up to 5 years) ]PFS was assessed by the investigator based on World Health Organization (WHO) criteria using radiographic tumor evaluations. Disease progression was defined as the appearance of any new lesion not previously identified or an estimated increase of 25% or more in existent bidimensionally or unidimensionally measurable lesions or progression of an existing non-measurable lesion. For bidimensionally measurable malignant lesions with an area of at least 2.0 centimeters squared (cm^2) an increase of 1.0 cm^2 was required and for unidimensionally measurable lesions of 1.0 cm or less an increase of 0.5 cm was required. PFS was defined as the number of days between date of randomization and date of documented disease progression or date of death. Kaplan Meier estimates of PFS are presented.
Secondary Outcome Measures :
- Percentage of Participants With Clinical Benefit [ Time Frame: 24 Months, End of Study (Up to 5 years) ]Clinical Benefit was defined as stable disease for ≥ six months or complete response or partial response.
- Duration of Response at 24 Months [ Time Frame: 24 Months ]Duration of response was defined as the number of days from the day complete response or partial response was first noted to the day of progression of disease, death or last follow-up.
- Time to Response at 24 Months [ Time Frame: 24 Months ]Time to response was defined as the number of days from the day of randomization to the day complete response or partial response was first noted.
- Overall Survival at 24 Months [ Time Frame: 24 Months ]Overall Survival is defined as the number of days from randomization to death.
- Percentage of Participants With Two-Year Survival [ Time Frame: 24 Months ]
- Percentage of Participants With Overall Tumor Response at 24 Months [ Time Frame: 24 Months ]Tumor Response levels were determined by the investigator and an Independent Response Evaluation Committee and Reconciled. Overall Response was defined as either complete response or partial response.
- Percentage of Participants With Best Tumor Response at 24 Months [ Time Frame: 24 Months ]Tumor Response levels were determined by the investigator and an Independent Response Evaluation Committee and Reconciled. Best Response was defined as the best response a patient achieves in the study.
- Percentage of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status at Final Visit Compared to Baseline [ Time Frame: Baseline, Final Visit (Up to 24 Months) ]
Participants rated their performance status using the ECOG Questionnaire on the following scale: 0=Fully active, perform all pre-disease activities without restriction; 1=Restricted in physically strenuous activity but ambulatory, carry out work of a light or sedentary nature; 2=Ambulatory, capable of self-care, unable to carry out any work activities, up and about more than >50% of waking hours; 3=Capable of limited self-care, confined to bed or chair >50% of waking hours; 4=Completely disabled, not capable of any self-care, totally confined to bed or chair; 5=Dead.
The percentage of participants in the following categories:
Improved: Score decrease from baseline. Unchanged: Score the same as baseline. Worse: Score increase from baseline.
- Duration of Response at End of Study [ Time Frame: End of Study (Up to 5 years) ]Duration of response was defined as the number of days from the day complete response or partial response was first noted to the day of progression of disease, death or last follow-up.
- Time to Response at End of Study [ Time Frame: End of Study (Up to 5 years) ]Time to response was defined as the number of days from the day of randomization to the day complete response or partial response was first noted.
- Percentage of Participants With Overall Tumor Response at End of Study [ Time Frame: End of Study (Up to 5 years) ]Tumor Response levels were determined by the investigator and an Independent Response Evaluation Committee and Reconciled. Overall Response was defined as either complete response or partial response.
- Percentage of Participants With Best Tumor Response at End of Study [ Time Frame: End of Study (Up to 5 years) ]Tumor Response levels were determined by the investigator and an Independent Response Evaluation Committee and Reconciled. Best Response was defined as the best response a patient achieves in the study.
- Number of Participants With Adverse Events [ Time Frame: Throughout the Study (Up to 5 years) ]Number of participants with adverse events as a measure for safety as assessed by the collection of adverse events, laboratory tests for Hematology and Serum Chemistry, clinical assessments and cardiac monitoring.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- postmenopausal women;
- metastatic breast cancer suitable for endocrine therapy;
- positive hormone receptor status;
- Human epidermal growth factor receptor 2 (HER2) overexpression.
Exclusion Criteria:
- patients on hormone replacement therapy;
- previous chemotherapy for metastatic disease;
- uncontrolled cardiac disease and history of cardiac failure.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00022672
Locations
Show 132 study locations
Sponsors and Collaborators
Hoffmann-La Roche
Genentech, Inc.
Investigators
| Study Director: | Clinical Trials | Hoffmann-La Roche |
| Responsible Party: | Hoffmann-La Roche |
| ClinicalTrials.gov Identifier: | NCT00022672 |
| Obsolete Identifiers: | NCT00112450 |
| Other Study ID Numbers: |
BO16216 |
| First Posted: | January 27, 2003 Key Record Dates |
| Results First Posted: | June 13, 2013 |
| Last Update Posted: | June 13, 2013 |
| Last Verified: | June 2013 |
Additional relevant MeSH terms:
|
Breast Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases Trastuzumab Anastrozole Antineoplastic Agents, Immunological Antineoplastic Agents |
Antineoplastic Agents, Hormonal Aromatase Inhibitors Steroid Synthesis Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Estrogen Antagonists Hormone Antagonists Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs |